As of 31 Dec 2025, 46 institutional investors reported holding $472,830,661 in principal (par value) of ASCENDIS PHARMA A/S - NOTE 2.250% 4/0.
| Period | Principal | Value | Change | Price (% of par) (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | $472,830,661 | $695,899,343 | -$14,076,693 | 141.67% | 46 |
| 2025 Q3 | $483,214,000 | $683,676,184 | -$186,644 | 136.38% | 41 |
| 2025 Q2 | $526,422,000 | $659,791,143 | -$19,673,568 | 125.31% | 41 |
| 2025 Q1 | $534,013,999 | $655,394,730 | -$1,900,121 | 118.55% | 40 |
| 2024 Q4 | $556,318,000 | $612,674,297 | -$16,374,567 | 110.04% | 41 |
| 2024 Q3 | $566,020,430 | $656,636,350 | -$1,520,196 | 116.54% | 42 |
| 2024 Q2 | $569,471,000 | $635,090,756 | +$11,704,865 | 111.5% | 37 |
| 2024 Q1 | $552,283,575 | $644,558,035 | -$19,758,059,780 | 115.55% | 37 |
| 2023 Q4 | $571,154,000 | $586,959,623 | +$12,691,698 | 102.78% | 34 |
| 2023 Q3 | $562,476,075 | $517,038,664 | -$2,688,912 | 91.88% | 34 |
| 2023 Q2 | $565,722,400 | $515,987,274 | +$515,987,274 | 91.25% | 35 |